In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time Cell therapy has drastically improved the scope of treatment for a number of diseases in the last few years. Now, engineered B cells are the latest approach in the field of cell therapy, having recently made it into clinical trials. But what exactly are B cells and how can they be engineered to treat diseases? […] January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2024 Five biotech companies taking Florida by storm Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies. January 16, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 12 Jan 2024Could natural killer cells transform Alzheimer’s treatment? Join Dr. Paul Song, CEO of NKGen Biotech, in a podcast exploring the revolutionary use of NK cells for Alzheimer’s treatment. January 12, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jan 2024 Ten NK cell therapy companies to look out for this year As biotechs raise funding to advance their NK cell therapy candidates in the clinic, here are ten companies in the space to watch out for. January 11, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Dec 2023 Nine biotech companies to watch in 2024 2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024. December 19, 2023 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 10 Nov 2023How biotech can mend a broken heart CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In this podcast, we investigate regenerative therapy with CellProthera’s CEO, Matthieu de Kalbermatten. While regenerative cell therapy is dependent on the patient’s own cells, and reliant […] November 10, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 27 Oct 2023Beyond Biotech podcast 69 – improving access to cell and gene therapy This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT), increasing access to these innovative treatments. Ori has developed a proprietary, full […] October 27, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 4 Oct 2023 CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off? Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […] October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jul 2023 Cell and gene therapy manufacturing: trends, advancements and challenges Cell and gene therapy manufacturing has been a pertinent topic for a while now, largely due to the fact it is such a complicated process, involving a number of moving parts and excessive costs. As such, figuring out how to make these types of therapies scalable, less time consuming and cost-effective is still an ongoing […] July 27, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 14 Jul 2023Beyond Biotech podcast 54 1:24 Labiotech news3:45 TolerogenixX This week, we have a conversation with Matthias Schaier, CEO of TolerogenixX, about tackling rejection of organs following transplantation. TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant […] July 14, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NK:IO awarded £1.6M grant to develop NK cell therapy NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […] July 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email